Tahoe Therapeutics, Arc Institute, and Biohub Partner to Generate the Largest Perturbation Dataset for Virtual Cell Models
Tahoe Therapeutics, Arc Institute, and Biohub announced a landmark initiative to generate the largest and most perturbation-rich single-cell dataset for virtual cell models. The effort is supported by a multi-institutional, multi-million dollar commitment by each of these groups, and represents the first collaboration of its kind at this scale. It extends the breakthroughs established with the perturbational datasets including Tahoe-100M, Arc’s scBaseCount, and Biohub’s CELLxGENE dataset.
Tahoe Therapeutics Welcomes Proven Discovery Leaders Wayne Spevak, Ph.D., and Ben Powell, Ph.D., to Advance Drug Discovery
Tahoe Therapeutics today announced the appointments of Wayne Spevak, Ph.D. as Vice President of Chemistry and Ben Powell, Ph.D. as Vice President of Drug Discovery, strengthening the company’s ability to translate AI-native biological insight into new medicines.
Tahoe Therapeutics Raises $30M to Build World’s Largest Dataset for Training AI Models of Human Cell
Tahoe Therapeutics today announced $30 million in new funding to build the definitive foundational dataset for training Virtual Cell Models. With this, the team will generate one billion single-cell datapoints, mapping one million drug-patient interactions, a scale previously impossible. The dataset will support the discovery of new precision medicines for cancer and beyond. Tahoe will also select a single partner to share the data and accelerate translation to clinical outcomes.
